This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by IJdo, J W Articles by Greco, T P Search for Related Content PubMed PubMed Citation Articles by IJdo, J W Articles by Greco, T P Social Bookmarking                         What's this?

Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS?

Section of Rheumatology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut

A M Conti-Kelly

P Greco

M Abedi

St Mary's Hospital, Waterbury, Connecticut

M Amos

Dia Sorim, Inc., Stillwater, Minnesota

J M Provenzale

Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA

T P Greco

Section of Rheumatology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut; St Mary's Hospital, Waterbury, Connecticut

Objective: To describe the frequency, clinical, and laboratory features of patients diagnosed with multiple sclerosis (MS) or MS-like illnesses (MSL) among a large, prospectively followed cohort of anti-phospholipid antibody (aPL)-positive patients.

Methods: Between 1990 and 1995 patients referred to a university-affiliated rheumatology clinic were prospectively evaluated for aPL based on questionnaires designed to detect aPL-related symptoms and/or a family history of aPL-related illnesses. Magnetic resonance imaging (MRI) was performed when significant neurological features were present. A subgroup of all patients diagnosed with MS or MSL was identified and their clinical, laboratory, and imaging findings were reviewed.

Results: Of 322 patients evaluated for aPL-related symptoms or events, 189 (59%) were positive for at least one class of aPL. Twenty-six of 322 patients (8%) carried a diagnosis of MS or MSL, either at the initial evaluation or during the study period. Twenty-three of the 26 individuals (88%) tested positive for aPL, while the remaining 3 (11%) tested repeatedly negative. Eighteen of the 23 patients (78%) had either more than one class of aPL or had multiple positive titers. IgM aCL was noted in 18 of the 23 patients (78%). Oligoclonal bands were noted in five patients. Antinuclear antibodies (ANA) and low complement levels were frequently observed. Blinded MRI readings showed lesions consistent with MS in the majority of cases. Clinically, 7 patients had transverse myelitis (TM), while optic neuritis (ON) was present in 8 patients. Most patients had either occult symptoms of rheumatic disease or contributory family histories. None had a defined underlying connective-tissue disease.

Conclusion: A substantial number of aPL-positive patients have a concurrent diagnosis of MS or MSL, frequently presenting with elevated IgM aCL, optic neuritis, and transverse myelitis. The anti-phospholipid syndrome (APS) should be strongly considered as an alternative diagnosis to MS in these patients.

Key Words: ANA • anti-phospholipid antibody • lupus • multiple sclerosis

Lupus, Vol. 8, No. 2, 109-115 (1999)
DOI: 10.1191/096120399678847461


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M Podbielska and E. Hogan Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis? Multiple Sclerosis, September 1, 2009; 15(9): 1011 - 1029. [Abstract] [PDF]

				A Theodoridou and L Settas Demyelination in rheumatic diseases Postgrad. Med. J., March 1, 2008; 84(989): 127 - 132. [Abstract] [Full Text] [PDF]

				B. Yamout, T. El-Hajj, W. Barada, and I. Uthman Successful treatment of refractory neuroSjogren with Rituximab Lupus, July 1, 2007; 16(7): 521 - 523. [Abstract] [PDF]

				D Paran, J Chapman, A D Korczyn, O Elkayam, O Hilkevich, G B Groozman, D Levartovsky, I Litinsky, D Caspi, Y Segev, et al. Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis Ann Rheum Dis, April 1, 2006; 65(4): 525 - 528. [Abstract] [Full Text] [PDF]

				A Theodoridou and L Settas Demyelination in rheumatic diseases. J. Neurol. Neurosurg. Psychiatry, March 1, 2006; 77(3): 290 - 295. [Abstract] [Full Text] [PDF]

				S. Ferreira, D. P. D'Cruz, and G. R. V. Hughes Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology, April 1, 2005; 44(4): 434 - 442. [Abstract] [Full Text] [PDF]

				J Sastre-Garriga and X Montalban APS and the brain Lupus, December 1, 2003; 12(12): 877 - 882. [Abstract] [PDF]

				O Heinzlef, B Weill, C Johanet, V Sazdovitch, S Caillat-Zucman, E Tournier-Lasserve, and E Roullet Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics J. Neurol. Neurosurg. Psychiatry, May 1, 2002; 72(5): 647 - 649. [Abstract] [Full Text] [PDF]

				G. Ruiz-Irastorza and M.A. Khamashta Warfarin for multiple sclerosis? QJM, August 1, 2000; 93(8): 497 - 499. [Full Text] [PDF]

				A Aziz, M D Conway, H J Robertson, L R Espinoza, and W A Wilson Acute optic neuropathy and transverse myelopathy in patients with antiphospholipid antibody syndrome: Favorable outcome after treatment with anticoagulants and glucocorticoids Lupus, May 1, 2000; 9(4): 307 - 310. [Abstract] [PDF]

				M Rovaris, B Viti, G Ciboddo, S Gerevini, R Capra, G Iannucci, G Comi, and M Filippi Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study J. Neurol. Neurosurg. Psychiatry, February 1, 2000; 68(2): 170 - 177. [Abstract] [Full Text] [PDF]